يعرض 41 - 60 نتائج من 18,658 نتيجة بحث عن '(( significantly ((linear decrease) OR (a decrease)) ) OR ( significantly improve decrease ))', وقت الاستعلام: 0.51s تنقيح النتائج
  1. 41

    Analysis of the Nugent score before (T=0) and after (T=1) the use of the vaginal gel. Number of participants and respective percentages of Nugent scores before and after the intervention. A statistically significant decrease in Nugent scores was observed after the intervention (p value =0.0047). حسب Adriana Bittencourt Campaner (21175462)

    منشور في 2025
    "…Number of participants and respective percentages of Nugent scores before and after the intervention. A statistically significant decrease in Nugent scores was observed after the intervention (p value =0.0047).…"
  2. 42

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  3. 43

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  4. 44

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

    منشور في 2025
    "…UCB-Treg and ruxolitinib combination also downregulates the soluble form of inflammatory cytokines including IFN-γ, IP-10, TNF-α, IL-6, sCD40L, IL-17A, IL-17F, IL-1α, and LIF in cocultures. The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …"
  5. 45
  6. 46
  7. 47
  8. 48
  9. 49
  10. 50
  11. 51
  12. 52
  13. 53
  14. 54
  15. 55

    Sampling point (Source: حسب Yonggang Huang (223155)

    منشور في 2025
    الموضوعات:
  16. 56
  17. 57
  18. 58
  19. 59
  20. 60